Question 1

What is Levi Garraway?

Accepted Answer

Levi Garraway is a Person.

Question 2

How often does Levi Garraway appear in global news?

Accepted Answer

Tracked across 4 news events drawn from 53 articles.

Question 3

When was Levi Garraway first tracked by Ergen?

Accepted Answer

First tracked on Apr 21, 2026.

Question 4

When was Levi Garraway last mentioned in news?

Accepted Answer

Last active on Jun 11, 2026.

Question 5

What is Levi Garraway's current news sentiment?

Accepted Answer

Aggregate sentiment score: 18 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Levi Garraway in global news coverage?

Accepted Answer

Attention score of 8, derived from article volume and coverage intensity across 4 events.

Question 7

What is the most recent event involving Levi Garraway?

Accepted Answer

Roche Licenses Nurix Therapeutics' Bexobrutideg (Jun 07, 2026, 22 articles).

Question 8

Who is Levi Garraway most connected to?

Accepted Answer

Top relationships: Roche, Roche.

Question 9

How did the "Roche Licenses Nurix Therapeutics' Bexobrutideg" event impact Levi Garraway?

Accepted Answer

Levi Garraway, Roche's chief medical officer, expressed confidence in bexobrutideg's potential to significantly advance treatment for complex blood cancers and other diseases, highlighting Roche's strategic vision for the drug.

Question 10

How did the "Genentech's Giredestrant NDA Accepted" event impact Levi Garraway?

Accepted Answer

Levi Garraway>>>, chief medical officer at F. Hoffmann-La Roche — Genentech>>>, provided commentary on the significance of giredestrant as a major advance in endocrine therapy for early-stage ER-positive breast cancer.

Question 11

How did the "Genentech Presents Positive Obesity Drug Data" event impact Levi Garraway?

Accepted Answer

Levi Garraway, as the chief medical officer and head of Global Product Development at F. Hoffmann-La Roche — Genentech, commented on the strength of the obesity portfolio and the potential for individualized treatment options.

Question 12

How did the "FDA accepts Roche Tecentriq sBLA" event impact Levi Garraway?

Accepted Answer

Levi Garraway>>>, Roche>>>'s Chief Medical Officer, commented on the significance of the filing acceptance for Atezolizumab>>>.

Question 13

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.